Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
28 01 2019
Historique:
received: 14 02 2018
accepted: 10 12 2018
entrez: 30 1 2019
pubmed: 30 1 2019
medline: 22 7 2020
Statut: epublish

Résumé

Parkinson's disease (PD) is associated with diverse clinical manifestations including motor and non-motor signs and symptoms, and emerging biomarkers. We aimed to reveal the heterogeneity of PD to define subtypes and their progression rates using an automated deep learning algorithm on the top of longitudinal clinical records. This study utilizes the data collected from the Parkinson's Progression Markers Initiative (PPMI), which is a longitudinal cohort study of patients with newly diagnosed Parkinson's disease. Clinical information including motor and non-motor assessments, biospecimen examinations, and neuroimaging results were used for identification of PD subtypes. A deep learning algorithm, Long-Short Term Memory (LSTM), was used to represent each patient as a multi-dimensional time series for subtype identification. Both visualization and statistical analysis were performed for analyzing the obtained PD subtypes. As a result, 466 patients with idiopathic PD were investigated and three subtypes were identified. Subtype I (Mild Baseline, Moderate Motor Progression) is comprised of 43.1% of the participants, with average age 58.79 ± 9.53 years, and was characterized by moderate functional decay in motor ability but stable cognitive ability. Subtype II (Moderate Baseline, Mild Progression) is comprised of 22.9% of the participants, with average age 61.93 ± 6.56 years, and was characterized by mild functional decay in both motor and non-motor symptoms. Subtype III (Severe Baseline, Rapid Progression) is comprised 33.9% of the patients, with average age 65.32 ± 8.86 years, and was characterized by rapid progression of both motor and non-motor symptoms. These subtypes suggest that when comprehensive clinical and biomarker data are incorporated into a deep learning algorithm, the disease progression rates do not necessarily associate with baseline severities, and the progression rate of non-motor symptoms is not necessarily correlated with the progression rate of motor symptoms.

Identifiants

pubmed: 30692568
doi: 10.1038/s41598-018-37545-z
pii: 10.1038/s41598-018-37545-z
pmc: PMC6349906
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

797

Références

J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):343-8
pubmed: 15716523
Int J Geriatr Psychiatry. 2005 Jul;20(7):629-34
pubmed: 16021666
Dement Geriatr Cogn Disord. 2006;22(4):312-9
pubmed: 16940725
Neurology. 2006 Dec 26;67(12):2176-85
pubmed: 17190940
Brain. 2007 Jul;130(Pt 7):1787-98
pubmed: 17535834
J Neurol. 2008 May;255(5):716-22
pubmed: 18344057
Brain. 2009 Nov;132(Pt 11):2947-57
pubmed: 19759203
Mov Disord. 2010 Jun 15;25(8):969-78
pubmed: 20535823
Mov Disord. 2011 Feb 15;26(3):457-63
pubmed: 21229621
Mov Disord. 2011 Jan;26(1):51-8
pubmed: 21322019
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9
pubmed: 21499542
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Neurology. 1990 Oct;40(10):1529-34
pubmed: 2215943
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S467-72
pubmed: 22588767
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503
Mov Disord. 2013 Feb;28(2):183-9
pubmed: 23436633
JAMA Neurol. 2013 Oct;70(10):1277-87
pubmed: 23979011
JAMA Neurol. 2014 Apr;71(4):499-504
pubmed: 24514863
JAMA Neurol. 2015 Aug;72(8):863-73
pubmed: 26076039
J Parkinsons Dis. 2015;5(2):269-79
pubmed: 26405788
Neurology. 2016 Apr 12;86(15):1400-1407
pubmed: 26865518
Parkinsonism Relat Disord. 2016 Jul;28:137-40
pubmed: 27158121
Sci Rep. 2016 May 17;6:26094
pubmed: 27185194
PLoS One. 2016 Oct 20;11(10):e0164762
pubmed: 27764160
JAMA. 2016 Dec 13;316(22):2402-2410
pubmed: 27898976
Nature. 2017 Feb 2;542(7639):115-118
pubmed: 28117445
Brain. 2017 Jul 1;140(7):1959-1976
pubmed: 28549077
Eur J Neurol. 2018 Sep 3;:null
pubmed: 30175887
Neural Comput. 1997 Nov 15;9(8):1735-80
pubmed: 9377276

Auteurs

Xi Zhang (X)

Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, USA.

Jingyuan Chou (J)

Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, USA.

Jian Liang (J)

Department of Automation, Tsinghua University, Beijing, China.

Cao Xiao (C)

AI for Healthcare, IBM Research, Cambridge, USA.

Yize Zhao (Y)

Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, USA.

Harini Sarva (H)

Department of Neurology, Weill Cornell Medical College, Cornell University, New York, USA.

Claire Henchcliffe (C)

Department of Neurology, Weill Cornell Medical College, Cornell University, New York, USA.

Fei Wang (F)

Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, USA. few2001@med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH